Lipoprotein(a), usually written as Lp(a) and pronounced “L-P-little-a,” is a cholesterol-carrying particle in your blood whose levels are almost entirely set by your genes. Unlike the LDL cholesterol that statins target, Lp(a) does not respond to diet, exercise, or most standard medications. Roughly one in five people worldwide carries enough of it to raise their risk of heart attack, stroke, and aortic valve disease, yet most have never had it measured. The science around Lp(a) has accelerated sharply in recent years, with new drugs in late-stage trials and growing calls for universal screening.
What Lp(a) Actually Is
Structurally, Lp(a) looks a lot like a regular LDL particle. It has the same cholesterol-rich core and the same apolipoprotein B100 on its surface. The difference is a second protein, apolipoprotein(a), physically tethered to the apoB100 by a chemical bond.1PubMed Central. Lipoprotein (a): structure, pathophysiology and clinical implications That extra protein is what makes Lp(a) uniquely dangerous: it resembles plasminogen, a molecule your body uses to dissolve blood clots, and it carries oxidized phospholipids that trigger inflammation in artery walls. The result is a particle that promotes plaque buildup, interferes with clot breakdown, and stirs up chronic inflammation all at once.
Lp(a) is found only in humans, Old World primates, and, oddly, the European hedgehog.2PubMed. Lipoprotein (a) Evolution: Possible Benefits and Harm. Genetic and Non-Genetic Factors Influencing its Plasma Levels This narrow distribution across species has puzzled researchers for decades. One hypothesis is that Lp(a) originally served a wound-healing function, binding to damaged tissue and recruiting immune cells. In an era of short lifespans and frequent injuries, that may have been a net positive. In modern humans living long enough to accumulate arterial damage over decades, the same biology turns harmful.
Why Your Genes Are Almost the Whole Story
Most risk factors for heart disease respond to lifestyle changes. Lp(a) is a stark exception. Your blood level is determined overwhelmingly by variants in the LPA gene, which codes for apolipoprotein(a). The gene contains a highly variable stretch of repeated segments called kringle IV repeats. The number of these repeats varies widely from person to person, and fewer repeats generally mean a smaller apolipoprotein(a), faster production in the liver, and higher Lp(a) concentrations in the blood.3PubMed Central. Human Genetics and the Causal Role of Lipoprotein(a) for Various Diseases
This genetic architecture is important for two reasons. First, it means your Lp(a) level is largely fixed from birth. You inherit it from your parents, and no amount of dietary fiber or treadmill time will substantially move it. Second, it provides what epidemiologists call a natural experiment: because gene variants that raise Lp(a) also raise cardiovascular risk, the link between Lp(a) and disease is almost certainly causal, not just a correlation.4PubMed Central. Human Genetics and the Causal Role of Lipoprotein(a) for Various Diseases
In practice, once Lp(a) levels stabilize after puberty, they stay relatively steady through most of adulthood. There are some fluctuations in women tied to hormonal shifts: levels can rise during pregnancy and again after menopause, both periods when cardiovascular risk also increases independently.5PubMed Central. Lipoprotein(a) throughout life in women Kidney dysfunction can also push levels upward. But day-to-day, year-to-year, your Lp(a) stays close to whatever your genes have set it at.
Levels Vary Dramatically Across Populations
One of the most striking things about Lp(a) is how unevenly it is distributed across racial and ethnic groups. In a large multi-ethnic study, the median Lp(a) concentration among people of African descent was about 27 mg/dL with relatively small apolipoprotein(a) isoforms, while people of Chinese descent had a median of roughly 8 mg/dL and the largest isoform sizes.6PubMed. Lipoprotein(a) Levels and the Risk of Myocardial Infarction Among 7 Ethnic Groups These are population-level averages, and individuals within every group span the full spectrum, but the differences are large enough to matter clinically.
A U.S.-based analysis looking at the commonly used threshold of 50 mg/dL found that roughly 63% of Black patients tested above it, compared with about 31% of Mexican patients. After adjusting for other factors, Black individuals had about two and a half times the odds of exceeding that cutoff, while Hispanic and Asian patients had lower odds.7PubMed Central. Lipoprotein(a) Levels in Disaggregated Racial and Ethnic Subgroups Across Atherosclerotic Cardiovascular Disease Risk Levels These disparities mean that Lp(a)-driven cardiovascular risk disproportionately affects Black populations, a fact that has historically been underappreciated in clinical cardiology.
How Lp(a) Damages Blood Vessels
The harm from Lp(a) comes through at least three overlapping pathways. The first and probably most important involves oxidized phospholipids. Lp(a) is the main carrier of these molecules in plasma, and when they arrive at the artery wall, they trigger an inflammatory cascade. They activate the cells lining blood vessels and recruit immune cells called monocytes, which burrow into the vessel wall and drive plaque formation.8PubMed Central. Oxidized Phospholipids on Lipoprotein(a) Elicit Arterial Wall Inflammation and an Inflammatory Monocyte Response in Humans People with Lp(a) above about 125 nmol/L show measurably increased arterial wall inflammation on imaging, consistent with this mechanism operating in real patients and not just in the lab.9PubMed. Lipoprotein(a): An underestimated inflammatory mastermind
The second pathway is prothrombotic. Because apolipoprotein(a) structurally resembles plasminogen, Lp(a) can compete with plasminogen’s role in dissolving clots. Multiple studies suggest that Lp(a) has both antifibrinolytic properties, meaning it slows clot breakdown, and procoagulant properties, meaning it encourages clot formation.10Pathophysiology of Haemostasis and Thrombosis. Lipoprotein(a) and Thrombocytes: Potential Mechanisms Underlying Cardiovascular Risk In an artery already narrowed by plaque, that combination makes a sudden blockage more likely.
The third pathway involves direct cholesterol delivery. Like LDL, Lp(a) carries cholesterol into the artery wall. Because standard lipid panels do not separate Lp(a) cholesterol from LDL cholesterol, some patients who appear to have well-controlled LDL actually still have significant cholesterol deposition driven by Lp(a).
Beyond Heart Attack
When most people hear about cholesterol risk, they think of heart attacks. Lp(a) certainly raises that risk, but its reach extends further.
Aortic valve stenosis, a condition in which the heart’s aortic valve gradually stiffens and narrows with calcium deposits, has one of the strongest links to Lp(a). In patients with aortic stenosis, those in the highest third of Lp(a) levels had faster calcium accumulation in the valve, faster progression of the disease on echocardiography, and a higher rate of valve replacement or death compared to those with lower levels.11PubMed Central. Lipoprotein(a) and Oxidized Phospholipids Promote Valve Calcification in Patients With Aortic Stenosis Research shows that Lp(a) above 30 mg/dL was independently associated with early aortic valve calcification even in people without established valve disease, after controlling for obesity, sex, and age.12European Heart Journal. The potential role of elevated lipoprotein(a) in the early stages of aortic valve stenosis In lab experiments, Lp(a) directly induced the bone-forming changes in valve cells that lead to calcification, and blocking its oxidized phospholipids stopped the process.13PubMed Central. Lipoprotein(a) and Oxidized Phospholipids Promote Valve Calcification in Patients With Aortic Stenosis
Stroke risk also rises with Lp(a). In a large general-population study, people with Lp(a) above roughly 93 mg/dL had about 60% higher risk of ischemic stroke compared to those with the lowest levels, and genetic analyses confirmed the relationship was causal.14PubMed. Elevated Lipoprotein(a) and Risk of Ischemic Stroke A systematic review and meta-analysis found that elevated Lp(a) was significantly associated with ischemic stroke risk as well as with the large-artery-atherosclerosis subtype and intracerebral hemorrhage.15Scientific Reports. Lipoprotein (a) level as a risk factor for stroke and its subtype: A systematic review and meta-analysis
Peripheral artery disease, the narrowing of blood vessels that supply the legs, is another area where Lp(a) has clear effects. People with the highest Lp(a) levels (at or above the 99th percentile) had roughly three times the risk of peripheral artery disease and about twice the risk of abdominal aortic aneurysm compared to those below the median. For people who already had peripheral artery disease, very high Lp(a) tripled the rate of major adverse limb events like amputation or acute limb ischemia.16PubMed. Lipoprotein(a) and Risks of Peripheral Artery Disease, Abdominal Aortic Aneurysm, and Major Adverse Limb Events
Why Standard Treatments Do Not Work on Lp(a)
If you have been told your Lp(a) is high, the first thing to understand is that the most commonly prescribed cholesterol drugs barely touch it. A systematic review and meta-analysis of statin trials found that no type or intensity of statin therapy produced a meaningful change in Lp(a) levels compared to placebo.17European Journal of Preventive Cardiology. Statin therapy and lipoprotein(a) levels: a systematic review and meta-analysis Statins remain critical for lowering LDL cholesterol and reducing overall cardiovascular risk, but they leave the Lp(a) component of that risk untouched.
PCSK9 inhibitors, the injectable drugs like evolocumab and alirocumab that dramatically lower LDL, do modestly reduce Lp(a) as well. Analysis across multiple trials showed evolocumab lowered Lp(a) by roughly 25% on average, and the effect held up over a year of treatment.18Journal of Lipid Research. PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor’s role Alirocumab showed a similar reduction of about 22%.19PubMed. PCSK9 Inhibition with alirocumab increases the catabolism of lipoprotein(a) particles in statin-treated patients with elevated lipoprotein(a) That is helpful but not dramatic when you consider that some patients need Lp(a) reductions of 80% or more to reach safe levels.
Lipoprotein apheresis, a procedure somewhat like dialysis that physically filters lipoproteins out of the blood, can drastically lower Lp(a) in a single session. Retrospective analyses of German cohorts found the annual rate of major cardiovascular events dropped steeply once patients began regular apheresis, though these studies lacked control groups, so the true size of the benefit remains uncertain.20Journal of Lipid Research. Lipoprotein apheresis to treat elevated lipoprotein (a) Despite being available and approved, apheresis is used by only a small fraction of eligible patients, partly because it requires visits to a specialized center every one to two weeks and is time-consuming.21PubMed. Lipoprotein Apheresis: Utility, Outcomes, and Implementation in Clinical Practice: A Scientific Statement From the American Heart Association
New Drugs That Target Lp(a) Directly
The real excitement in this space comes from a new class of drugs designed specifically to shut down Lp(a) production in the liver. These work at the genetic level, intercepting the messenger RNA that instructs liver cells to make apolipoprotein(a).
Pelacarsen is an antisense oligonucleotide, a short stretch of synthetic DNA that binds to and destroys the LPA gene’s mRNA before it can be translated into protein.22PubMed Central. Pelacarsen for lowering lipoprotein(a): implications for patients with chronic kidney disease It is given as a monthly injection and is currently in a large phase 3 cardiovascular outcomes trial. If it demonstrates that lowering Lp(a) actually reduces heart attacks and strokes — and not just the blood level itself — it would be the first drug ever approved specifically for Lp(a).
Olpasiran uses a different mechanism called small interfering RNA (siRNA) to achieve the same goal: degrading the mRNA for apolipoprotein(a). In its phase 2 trial, higher doses of olpasiran administered every 12 weeks reduced circulating Lp(a) by more than 95%.23PubMed. The Off-Treatment Effects of Olpasiran on Lipoprotein(a) Lowering: OCEAN(a)-DOSE Extension Period Results That is a strikingly large reduction, far beyond what any existing therapy achieves, and the effect persisted for months even after stopping the drug.
A third approach, muvalaplin, is notable because it is an oral pill rather than an injection. Instead of stopping Lp(a) production, muvalaplin blocks the assembly of the Lp(a) particle by preventing apolipoprotein(a) from linking to LDL. Results from its early clinical trial have been published, and the oral route would obviously be more convenient for patients than regular injections.24PubMed Central. Oral Muvalaplin for Lowering of Lipoprotein(a): A Randomized Clinical Trial
None of these drugs is approved yet. The central unanswered question is whether lowering Lp(a) to very low levels actually translates into fewer cardiovascular events. The genetic evidence strongly suggests it should, but medicine requires proof from randomized trials. Those results are expected within the next few years.
The Measurement Problem
Even measuring Lp(a) accurately is harder than it sounds. The particle comes in many sizes because of the variable number of kringle IV repeats in apolipoprotein(a), and this size variation creates headaches for lab assays. Many common assays use antibodies that bind to the kringle repeats themselves, which means they over-count large particles and under-count small ones.25PubMed Central. Lp(a): When and how to measure it
Results can be reported in two different units: milligrams per deciliter (mg/dL), which measures the mass of the whole particle, or nanomoles per liter (nmol/L), which counts the number of apolipoprotein(a) molecules. You might assume there is a simple conversion factor between the two, but there is not. The ratio between molar concentration and mass varies depending on the patient’s isoform size, the assay method used, and even the threshold being evaluated. Ratios range from below 1 to above 5 depending on these factors.26PubMed. Relationship of lipoprotein(a) molar concentrations and mass according to lipoprotein(a) thresholds and apolipoprotein(a) isoform size The field is moving toward reporting in nmol/L as the preferred standard because it better reflects the actual number of Lp(a) particles in circulation, but many labs still report in mg/dL. If you get a result, note the units carefully, and do not try to convert one to the other using a fixed multiplier.
The commonly referenced risk thresholds are above 50 mg/dL or above 125 nmol/L, but these are approximate equivalents that may not hold for every individual.
Should Everyone Be Tested?
Because Lp(a) is genetically determined and does not change much over a lifetime, a single measurement is usually enough. The European Atherosclerosis Society has recommended that every adult get Lp(a) measured at least once to understand their baseline risk. In the United States, guidelines have been slower to catch up, though cardiology organizations increasingly support testing in people with a personal or family history of early heart disease, unexplained cardiovascular events, or aggressive atherosclerosis that seems out of proportion to their standard risk factors.
Cascade screening, testing family members of someone found to have high Lp(a), appears to be a particularly efficient strategy. In one study, screening children and siblings of adults with elevated Lp(a) (above 50 mg/dL) identified a new case of elevated Lp(a) for every two people tested.27PubMed. Cascade testing of children and adolescents for elevated Lp(a) in pedigrees with familial hypercholesterolaemia In contrast, testing children of adults who had familial hypercholesterolemia but normal Lp(a) only turned up one case per seven or eight tested.28PubMed. Cascade testing of children and adolescents for elevated Lp(a) in pedigrees with familial hypercholesterolaemia The approach works in reverse too: when children attending a pediatric lipid clinic were used as index cases, screening their adult relatives effectively identified asymptomatic family members at risk.29PubMed. Cascade screening for elevated Lp(a) in relatives of children who visited the pediatric lipid clinic: yield of daily clinical practice
Knowing your Lp(a) is high does not currently mean there is a specific drug to lower it, which is one reason some clinicians hesitate to test. But the information is still clinically useful. It can reclassify your overall cardiovascular risk: one study found that adding Lp(a) to standard risk prediction models reclassified about 21% of people previously considered borderline or intermediate risk.30PubMed Central. Lipoprotein(a) Atherosclerotic Cardiovascular Disease Risk Score Development and Prediction in Primary Prevention From Real-World Data Similarly, an earlier analysis found meaningful reclassification among intermediate-risk individuals when Lp(a) was factored in.31European Journal of Preventive Cardiology. Lipoprotein(a) and cardiovascular disease: prediction, attributable risk fraction, and estimating benefits from novel interventions That reclassification can justify more aggressive management of the risk factors you can control: tighter LDL targets, blood pressure optimization, or starting aspirin or a PCSK9 inhibitor earlier than you otherwise would.
What High Lp(a) Means for You Right Now
If your Lp(a) comes back elevated and you feel frustrated that there is no magic bullet, that frustration is reasonable. The standard advice, which admittedly sounds unsatisfying, is to bear down harder on every other modifiable risk factor. Lower your LDL cholesterol as aggressively as possible, manage blood pressure, control blood sugar if it is an issue, and avoid smoking. The logic is straightforward: Lp(a) makes your arteries more vulnerable, so reducing every other source of damage buys the most protection while the field waits for purpose-built Lp(a) drugs to prove themselves in outcomes trials.
Niacin, which was once promoted as an Lp(a)-lowering supplement, deserves mention because many patients still ask about it. Niacin at high doses can lower Lp(a) by roughly 20 to 30%, but large trials of niacin for cardiovascular outcomes were disappointing, and the side effect profile at therapeutic doses is unpleasant. Most lipid specialists no longer recommend it specifically for Lp(a).
For people with very high Lp(a) and progressive atherosclerotic disease despite optimal treatment of everything else, lipoprotein apheresis remains an option. It requires a significant time commitment, but the American Heart Association has emphasized it is underused relative to its approved indications, and retrospective data suggest meaningful reductions in cardiovascular events.32PubMed. Lipoprotein Apheresis: Utility, Outcomes, and Implementation in Clinical Practice: A Scientific Statement From the American Heart Association If your cardiologist has not discussed it, and you have recurrent events despite good LDL control, it is worth raising.
The broader picture is that Lp(a) has spent decades as a neglected corner of lipidology, known to researchers but rarely tested in clinical practice. That is changing. The genetic evidence for causality is as strong as it gets outside a randomized trial, the new therapies can lower levels by 95% or more, and the outcomes data that will make or break the whole field are on their way. For the roughly 20% of people walking around with high Lp(a) and no idea, getting tested now at least puts the information on the table.